Verzenio
E133651
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Verzenio canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T1168575 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Verzenio Context triple: [Eli Lilly and Company, notableProduct, Verzenio]
-
A.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
B.
Imbruvica
Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
-
C.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
D.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
E.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Verzenio Target entity description: Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
A.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
B.
Imbruvica
Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
-
C.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
D.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
E.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
- F. None of above. chosen
Statements (46)
| Predicate | Object |
|---|---|
| instanceOf |
CDK4/6 inhibitor
ⓘ
cancer medication ⓘ prescription medication ⓘ small molecule drug ⓘ |
| approvalYear | 2017 (FDA, United States) ⓘ |
| approvedFor |
adjuvant treatment of HR-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence
ⓘ
men with HR-positive, HER2-negative advanced breast cancer ⓘ postmenopausal women with HR-positive, HER2-negative advanced breast cancer ⓘ |
| ATCCode | L01EF03 ⓘ |
| commonSideEffect |
abdominal pain
ⓘ
diarrhea ⓘ fatigue ⓘ nausea ⓘ neutropenia ⓘ |
| contraindication | known hypersensitivity to abemaciclib ⓘ |
| developer | Eli Lilly and Company ⓘ |
| dosageForm | tablet ⓘ |
| hasActiveIngredient | abemaciclib ⓘ |
| hasDrugClass | cyclin-dependent kinase inhibitor ⓘ |
| hasGenericName | abemaciclib ⓘ |
| indication |
HER2-negative breast cancer
ⓘ
advanced breast cancer ⓘ early breast cancer at high risk of recurrence ⓘ hormone receptor–positive breast cancer ⓘ metastatic breast cancer ⓘ |
| legalStatus | prescription-only ⓘ |
| manufacturer | Eli Lilly and Company ⓘ |
| mechanismOfAction | inhibits CDK4 and CDK6 to block cell cycle progression from G1 to S phase ⓘ |
| metabolism | CYP3A4 substrate ⓘ |
| pregnancyCategory | can cause fetal harm ⓘ |
| regulatoryApproval |
EMA-approved
ⓘ
FDA-approved ⓘ |
| requiresMonitoring |
complete blood counts
ⓘ
liver function tests ⓘ |
| routeOfAdministration | oral ⓘ |
| seriousSideEffect |
hepatotoxicity
ⓘ
interstitial lung disease ⓘ venous thromboembolism ⓘ |
| takenWith | or without food ⓘ |
| targets |
CDK4
ⓘ
CDK6 ⓘ |
| therapeuticArea | oncology ⓘ |
| usedAs | monotherapy in certain settings ⓘ |
| usedWith |
aromatase inhibitors
ⓘ
endocrine therapy ⓘ fulvestrant ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Verzenio Description of subject: Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.